Nova Eye Medical (AU:EYE)
ASX:EYE
Want to see AU:EYE full AI Analyst Report?
EYE Stock Chart & Stats
AU$0.13
-AU$0.01(-5.26%)
At close: 4:00 PM EST
AU$0.13
-AU$0.01(-5.26%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$0.21
Previous CloseN/A
Volume155.74K
Average Volume (3M)204.72K
Market Cap
AU$30.62M
Enterprise ValueAU$35.08M
Total Cash (Recent Filing)AU$2.62M
Total Debt (Recent Filing)AU$4.94M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding284,868,300
10 Day Avg. Volume176,528
30 Day Avg. Volume204,722
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.43
Price to Sales (P/S)0.93
P/FCF Ratio-4.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$33.75M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent top-line growth indicates product traction and market adoption. Sustained revenue expansion provides a base for scale economies, supports future margin recovery if cost control improves, and gives management room to invest in commercialization and R&D over the next several quarters.
Low LeverageVery low financial leverage reduces refinancing and bankruptcy risk, preserving strategic flexibility. With limited debt obligations the company can prioritize investment in product development or clinical programmes and withstand continued operating losses without immediate solvency pressure.
Medical Devices Industry ExposureOperating in the medical devices sector provides structural tailwinds from aging populations, procedural volume growth, and technology adoption. These secular trends support durable demand for device innovation and create a multi-quarter runway for revenue and clinical adoption if execution remains consistent.
Bears Say
Margin CompressionA sharp decline in gross margin signals rising cost of goods sold or pricing pressure that undermines core profitability. If sustained, margin erosion limits operating leverage, lengthens time to break-even, and reduces cash generation capacity despite revenue growth.
Negative Cash GenerationPersistent negative operating and free cash flows indicate the business is not yet self-funding operations. Over months this necessitates external financing or equity dilution, constrains investment choices, and heightens the importance of preserving cash while pursuing commercialization.
Ongoing Losses / Negative ROESustained net losses and negative ROE mean the company is not generating returns on shareholders' capital. This undermines long-term shareholder value, may limit ability to attract non-dilutive funding, and requires a demonstrable path to profitability to restore investor confidence.
Nova Eye Medical News
EYE FAQ
What was Nova Eye Medical’s price range in the past 12 months?
Nova Eye Medical lowest share price was AU$0.10 and its highest was AU$0.20 in the past 12 months.
What is Nova Eye Medical’s market cap?
Nova Eye Medical’s market cap is AU$30.62M.
When is Nova Eye Medical’s upcoming earnings report date?
Nova Eye Medical’s upcoming earnings report date is Aug 26, 2026 which is in 63 days.
How were Nova Eye Medical’s earnings last quarter?
Nova Eye Medical released its earnings results on Feb 25, 2026. The company reported -AU$0.012 earnings per share for the quarter, missing the consensus estimate of -AU$0.005 by -AU$0.007.
Is Nova Eye Medical overvalued?
According to Wall Street analysts Nova Eye Medical’s price is currently Overvalued.
Does Nova Eye Medical pay dividends?
Nova Eye Medical pays a Weekly dividend of AU$0.414 which represents an annual dividend yield of N/A. See more information on Nova Eye Medical dividends here
What is Nova Eye Medical’s EPS estimate?
Nova Eye Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nova Eye Medical have?
Nova Eye Medical has 284,868,300 shares outstanding.
What happened to Nova Eye Medical’s price movement after its last earnings report?
Nova Eye Medical reported an EPS of -AU$0.012 in its last earnings report, missing expectations of -AU$0.005. Following the earnings report the stock price went down -3.125%.
Which hedge fund is a major shareholder of Nova Eye Medical?
Currently, no hedge funds are holding shares in AU:EYE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nova Eye Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-40.41%
Trailing 12-Months
Asset Growth
-0.64%
Trailing 12-Months
Company Description
Nova Eye Medical
Nova Eye Medical Limited specializes in the creation, advancement, distribution, marketing, sale, and servicing of surgical equipment dedicated to treating glaucoma. Its diverse product line features iTrack, a surgical system engineered to decrease intraocular pressure (IOP) in adult patients with open-angle glaucoma, and iTrack Advance, an innovative system promoting natural ocular fluid drainage. Furthermore, the company provides Molteno3, a glaucoma drainage device for individuals suffering from severe or intricate forms of the condition, alongside 2RT, a proprietary laser technology employed to address early to intermediate stages of age-related macular degeneration. With a presence spanning Australia, the United States, Europe, the Asia Pacific, and other international markets, the company, originally established in 1985 as Ellex Medical Lasers Limited, officially became Nova Eye Medical Limited in July 2020. Its corporate headquarters are situated in Kent Town, Australia.
Technical Analysis
Cochlear
―
Compumedics Limited
―
Somnomed Limited
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―
Options Prices
Currently, No data available
---